• PDF / 169,929 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 18 Downloads / 130 Views

DOWNLOAD

REPORT

---

1 S

Radiation dermatitis: case report A 55-year-old woman developed radiation dermatitis during treatment with trastuzumab-emtansine for invasive breast cancer [route and dosage not stated]. The woman was diagnosed with a large multifocal cT2N0 ER+ PR- HER2+ grade 2 invasive ductal carcinoma of the right breast in January 2019. Then, she received neoadjuvant systemic therapy with trastuzumab, docetaxel and pertuzumab, followed by a skin sparing mastectomy and sentinel node biopsy. An examination showed two foci of micrometastasis within 1 of 2 sentinel nodes. Based on residual disease following the surgery, she started receiving adjuvant trastuzumab emtansine [TDM-1] along with radiotherapy to the regional lymph nodes and chest wall. She developed radiation dermatitis in the second week of treatment as her skin findings felt to be more significant than expected based on skin dose. A topical prophylactic film was in placed over the woman’s breast mound for the duration of her treatment. She also developed skin desquamation. Then, the uncovered areas were managed with unspecified steroids. During the final week of treatment, she developed dry desquamation in the right inframammary fold. Thus, she received acetic-acid [vinegar] and silver sulfadiazine. Five days after completing radiation, she returned to clinic for the skin check-up. She was noted to have moist desquamation throughout the breast mound. This was assessed as grade 3 radiation dermatitis at the peak of toxicity. In the subsequent weeks, her skin recovered as expected. At her 3 month follow-up, her dermatitis completely resolved. It was considered that trastuzumabemtansine had contributed to the development of radiation dermatitis. Corbin KS, et al. Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1). Clinical and Translational Radiation Oncology 24: 99-101, Sep 2020. Available from: URL: http://doi.org/10.1016/j.ctro.2020.06.013 803500967

0114-9954/20/1821-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 12 Sep 2020 No. 1821